AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportTempus AI vs Atomwise
Tempus AI
VS
Atomwise
Verdict by Category
Detailed Comparison
Feature
Tempus AI
Atomwise
Pricing
CustomTempus operates multiple revenue streams with different access models.
Clinical genomic tests (xT, xG, xR, xF, xE) are ordered by physicians through the standard laboratory test ordering process. Pricing varies by test type and is typically covered by insurance for oncology patients. Tempus works directly with health systems to integrate ordering into EHR workflows.
Enterprise data platform access, Algos population health analytics, and biopharma research partnerships are priced through custom enterprise licensing agreements. Biopharma companies license Tempus's de-identified patient datasets and analytical services for drug development and clinical trial design.
Tempus is publicly traded on NASDAQ (ticker: TEM) since June 2024. Investor and enterprise partnership inquiries can be directed through tempus.com.
CustomAtomwise operates through enterprise partnership and co-development agreements — there is no self-serve access or published pricing.
Collaboration types include: sponsored research agreements (pharma/biotech pays Atomwise to run AI-powered hit discovery campaigns), co-development partnerships (shared IP and milestone/royalty structures), and academic program access for universities through the ATOM initiative.
New CEO Steve Worland is also steering Atomwise toward an internal proprietary drug pipeline, which will generate revenue through future licensing and partnering deals as candidates mature into preclinical and clinical stages.
Contact Atomwise through atomwise.com for partnership and collaboration inquiries.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Summary
AI precision medicine platform — genomic profiling, clinical insights, and trial matching for personalized cancer care
Deep learning for structure-based drug discovery — AtomNet screens 16B+ compounds to find hits for any disease target
Tempus AI Pros & Cons
Pros
- Publicly traded (NASDAQ: TEM) — one of the most credible precision medicine AI companies
- 7M+ de-identified patient records — one of the world's largest clinical-molecular datasets
- Comprehensive genomic testing across 6 test types covering all major oncology applications
- Tempus One AI provides real-time clinical insights at the point of care
- TIME Trial dramatically improves clinical trial matching and enrollment rates
- 3,800+ employees and $8.79B total capital raised since founding
- Expanding beyond oncology into neuropsychiatry, cardiology, and infectious disease
Cons
- Enterprise and institutional pricing — not accessible to individual clinicians or small practices
- Focused primarily on oncology and genomics — not a general-purpose clinical AI tool
- Genomic test turnaround requires laboratory processing time
- Data platform access and licensing requires formal agreements
- Some AI insights require institutional genomic data infrastructure to fully leverage
Atomwise Pros & Cons
Pros
- Invented deep learning for structure-based drug discovery in 2012 — true pioneer in the field
- AtomNet screens 16B+ compounds in under 2 days — fastest virtual screening at this scale
- 775+ collaborations and 250+ partners — most validated partnership network in AI drug discovery
- Tackles undruggable targets that traditional methods can't address
- Strong academic program: 40+ universities including Harvard, Stanford, and Duke
- New Foundation Model announced 2026 — next-generation AI for molecular discovery
- $226M+ raised from DCVC, Khosla, Y Combinator, Tencent, B Capital, and Baidu
Cons
- Early-stage company — no FDA-approved drugs from the platform yet
- Shifting focus from platform licensing to proprietary pipeline adds execution risk
- Smaller team (~100-250 employees) compared to larger AI drug discovery peers
- Revenue still modest at $5-25M range — pre-commercial stage
- Deep tech focus means long timelines before patient impact is realized